Clinical trials: Antipsychotic
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Pharmacogenetics, Healthy
Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers
The purpose of this study is to determine in healthy volunteers treated with typical or atypical antipsychotics -AP-, the relationship between genetic polymorphisms in cytochrome genes CYP2D6 (*3, *4, *5, *6 and Nxn) and CYP3A5…
- Trial name
- APSEP (NCT01259973)
- Testing
- Risperidone, Haloperidol
- Where
- 2 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Lurasidone Cardiotoxicity, Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.
- Conditions
- Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
- Trial name
- Lurasidone (NCT06695676)
- Testing
- Global Longitudinal Strain
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital